Lv2
148 积分 2024-08-19 加入
Table S2 from Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
2天前
已完结
Patient-Derived Tumor Xenografts Plus Ex Vivo Models Enable Drug Validation for Tenosynovial Giant Cell Tumors
16天前
已完结
Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
1个月前
已完结
International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic Neoplasms
7个月前
已关闭
First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
1年前
已完结
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
1年前
已完结
Inhaled Sedation in Acute Respiratory Distress Syndrome
1年前
已完结
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
1年前
已完结
Experience with Multiagent Chemotherapy for Osteosarcoma
1年前
已完结
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
1年前
已完结
皖公网安备34019202002308
